Company Release

30 August 2021 at 9:00 a.m. (Finnish time)

Nightingale Health Plc (”Nightingale”) has appointed internationally recognised scientific leader Jeffrey Barrett as Chief Scientific Officer. Barrett will join Nightingale’s management team as of 27 September 2021.

Jeffrey Barrett has held scientific leadership positions in some of the world’s most prominent health initiatives, and he is also a senior level business executive with proven track record in leading teams of scientists and engineers to build commercial health products and business growth. Barrett is joining Nightingale with a key strategic role translating scientific discoveries from Nightingale’s world-leading health data assets into commercial products. He will also help define Nightingale’s future strategic initiatives to further accelerate Nightingale’s global leadership in preventative health solutions.

Jeffrey Barrett joins Nightingale from the Wellcome Sanger Institute, in the United Kingdom, where he has led the world’s largest genomic surveillance effort for SARS-CoV-2 that led to the discovery of the Alpha variant, tracked the rise of the Delta variant and built tools to support response to outbreaks. Before that Barrett was Founding Director of Open Targets, a multi-million dollar public-private partnership in early stage drug discovery, and has held Chief Scientific Officer and Board Member positions at Genomics plc in the United Kingdom. Barrett holds a PhD degree from the University of Oxford and is author of more than 100 peer reviewed scientific publications with over 95,000 citations.

Teemu Suna, CEO and co-founder of Nightingale:

“We are on a global mission to bring tools of preventative health available to everyone. Nightingale’s technological, scientific and health data asset position is globally unique and we are now heavily accelerating leveraging our assets in commercial applications, that will be launched in the coming quarters. Therefore, I’m delighted to welcome Jeffrey to Nightingale. His distinguished international scientific and commercial experience will substantially help Nightingale reach its scientific, technological and commercial targets.”

Jeffrey Barrett, PhD:

“I’m incredibly impressed by how Nightingale has built their technology, and used it to create health data assets that offer truly unique insights into how to better predict and prevent disease. I’m also excited to be joining the inspirational team at Nightingale who have achieved so much and share my belief that advances in health technology can fundamentally change healthcare. I’m pleased to bring my expertise to help seize this opportunity and reach the ambitious mission of making advanced tools of preventative health available worldwide.”

For further information, please contact:
Teemu Suna, CEO

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale
Nightingale is a technology company transforming preventive health. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks, we are creating a world-leading health data platform that enables preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.